---
schema_version: "secwatch.filing_event.v1"
accession: "0001847903-22-000082"
form_type: "8-K"
ticker: "CNTA"
cik: "0001847903"
company_name: "Centessa Pharmaceuticals plc"
filed_at: "2022-11-10T23:59:59+00:00"
generated_at: "2026-06-21T23:53:25.531690+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Centessa Q3 net loss $53.9M, cash $444.8M; SerpinPC and LB101 on track

## Summary
- Net loss $53.9M in Q3 2022 vs $40.2M in Q3 2021; R&D spend $36.7M vs $25.9M.
- Cash $444.8M provides runway into 2026; no additional draw on Oberland facility.
- SerpinPC pivotal program: PRESent-5 observational study starting Q4 2022; Phase 2a OLE data at ASH Dec 10.
- LB101 IND submission for PD-L1xCD47 bispecific on track for late 2022.
- SerpinPC granted FDA Orphan Drug Designation in September 2022.

## SEC filing metadata
- accession: 0001847903-22-000082
- form_type: 8-K
- ticker: CNTA
- cik: 0001847903
- company_name: Centessa Pharmaceuticals plc
- filed_at: 2022-11-10T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1847903/000184790322000082/0001847903-22-000082-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1847903/000184790322000082/cnta-20221110.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001847903-22-000082
- JSON: https://secwatch.observer/filing/0001847903-22-000082.json
- Plain text: https://secwatch.observer/filing/0001847903-22-000082.txt

## Key facts
- Earnings Releases
  Centessa Pharmaceuticals plc reported the third quarter ended September 30, 2022 results: net income $53.9 million.
  - Period: the third quarter ended September 30, 2022
  - Net income: $53.9 million
  - Result: reported results
  source text: Centessa Pharmaceuticals plc (the “Company”) announced its financial results for the quarter ended September 30, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1847903/000184790322000082/0001847903-22-000082-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.